Annual FCF
N/A
December 1, 2024
Summary
- RARE annual free cash flow is not available.
Performance
RARE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly FCF
N/A
December 1, 2024
Summary
- RARE quarterly free cash flow is not available.
Performance
RARE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
N/A
December 1, 2024
Summary
- RARE TTM free cash flow is not available.
Performance
RARE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
RARE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
RARE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
Ultragenyx Pharmaceutical Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$68.61 M(-15.8%) | -$439.53 M(-10.8%) |
| Jun 2024 | - | -$81.47 M(-60.1%) | -$492.48 M(-9.4%) |
| Mar 2024 | - | -$203.94 M(+138.5%) | -$543.61 M(+4.2%) |
| Dec 2023 | -$521.57 M(-1.0%) | -$85.50 M(-29.7%) | -$521.57 M(-5.7%) |
| Sep 2023 | - | -$121.57 M(-8.3%) | -$553.38 M(+0.0%) |
| Jun 2023 | - | -$132.60 M(-27.1%) | -$553.20 M(+4.6%) |
| Mar 2023 | - | -$181.90 M(+55.1%) | -$528.78 M(+0.4%) |
| Dec 2022 | -$526.59 M(+27.9%) | -$117.31 M(-3.4%) | -$526.59 M(+9.8%) |
| Sep 2022 | - | -$121.39 M(+12.2%) | -$479.67 M(+9.4%) |
| Jun 2022 | - | -$108.18 M(-39.8%) | -$438.49 M(+5.5%) |
| Mar 2022 | - | -$179.71 M(+155.3%) | -$415.73 M(+1.0%) |
| Dec 2021 | -$411.79 M(+133.8%) | -$70.39 M(-12.2%) | -$411.79 M(-3.3%) |
| Sep 2021 | - | -$80.21 M(-6.1%) | -$425.79 M(+3.5%) |
| Jun 2021 | - | -$85.43 M(-51.4%) | -$411.33 M(+69.5%) |
| Mar 2021 | - | -$175.76 M(+108.3%) | -$242.64 M(+37.8%) |
| Dec 2020 | -$176.13 M(-52.4%) | -$84.40 M(+28.4%) | -$176.13 M(+0.5%) |
| Sep 2020 | - | -$65.75 M(-179.0%) | -$175.27 M(-13.7%) |
| Jun 2020 | - | $83.27 M(-176.2%) | -$203.06 M(-46.7%) |
| Mar 2020 | - | -$109.25 M(+30.8%) | -$380.63 M(+2.8%) |
| Dec 2019 | -$370.21 M(+25.6%) | -$83.54 M(-10.7%) | -$370.21 M(+7.7%) |
| Sep 2019 | - | -$93.54 M(-0.8%) | -$343.72 M(+7.3%) |
| Jun 2019 | - | -$94.30 M(-4.6%) | -$320.37 M(+5.6%) |
| Mar 2019 | - | -$98.83 M(+73.3%) | -$303.52 M(+3.0%) |
| Dec 2018 | -$294.64 M | -$57.05 M(-18.7%) | -$294.64 M(-8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$70.19 M(-9.4%) | -$320.32 M(+2.3%) |
| Jun 2018 | - | -$77.45 M(-13.9%) | -$313.16 M(+9.9%) |
| Mar 2018 | - | -$89.95 M(+8.7%) | -$284.90 M(+11.0%) |
| Dec 2017 | -$256.64 M(+49.9%) | -$82.72 M(+31.3%) | -$256.64 M(+15.5%) |
| Sep 2017 | - | -$63.03 M(+28.1%) | -$222.26 M(+16.4%) |
| Jun 2017 | - | -$49.20 M(-20.2%) | -$190.98 M(+2.4%) |
| Mar 2017 | - | -$61.69 M(+27.6%) | -$186.48 M(+8.9%) |
| Dec 2016 | -$171.16 M(+54.3%) | -$48.35 M(+52.3%) | -$171.16 M(+3.6%) |
| Sep 2016 | - | -$31.75 M(-29.0%) | -$165.18 M(-0.5%) |
| Jun 2016 | - | -$44.70 M(-3.6%) | -$166.02 M(+19.3%) |
| Mar 2016 | - | -$46.37 M(+9.5%) | -$139.19 M(+25.5%) |
| Dec 2015 | -$110.93 M(+137.1%) | -$42.37 M(+30.0%) | -$110.93 M(+36.2%) |
| Sep 2015 | - | -$32.58 M(+82.3%) | -$81.47 M(+35.0%) |
| Jun 2015 | - | -$17.87 M(-1.4%) | -$60.36 M(+12.4%) |
| Mar 2015 | - | -$18.12 M(+40.4%) | -$53.71 M(+14.8%) |
| Dec 2014 | -$46.78 M(+48.0%) | -$12.91 M(+12.5%) | -$46.78 M(+6.9%) |
| Sep 2014 | - | -$11.47 M(+2.2%) | -$43.78 M(+11.5%) |
| Jun 2014 | - | -$11.22 M(+0.2%) | -$39.26 M(+8.1%) |
| Mar 2014 | - | -$11.19 M(+13.0%) | -$36.33 M(+14.9%) |
| Dec 2013 | -$31.61 M(+132.5%) | -$9.90 M(+42.5%) | -$31.61 M(+45.6%) |
| Sep 2013 | - | -$6.95 M(-16.1%) | -$21.70 M(+47.1%) |
| Jun 2013 | - | -$8.29 M(+28.1%) | -$14.76 M(+128.1%) |
| Mar 2013 | - | -$6.47 M | -$6.47 M |
| Dec 2012 | -$13.60 M(+113.3%) | - | - |
| Dec 2011 | -$6.37 M | - | - |
FAQ
- What is the all time high annual FCF for Ultragenyx Pharmaceutical?
- What is the all time high quarterly FCF for Ultragenyx Pharmaceutical?
- What is the all time high TTM FCF for Ultragenyx Pharmaceutical?
What is the all time high annual FCF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual free cash flow is -$6.37 M
What is the all time high quarterly FCF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly free cash flow is $83.27 M
What is the all time high TTM FCF for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM free cash flow is -$6.47 M